![The Scope Radio show](https://d3dthqtvwic6y7.cloudfront.net/podcast-covers/000/062/269/small/the-scope-radio.jpg)
Summary: There’s a new treatment for patients with ALK+ (positive) non-small-cell lung cancer (NSCLC), which can occur in non-smoking lung cancer patients. Previously in clinical trial at Huntsman Cancer Institute, the new drug, Zykadia™/ ceritinib, is part of a new generation of treatments that targets a specific genetic defect in the tumor. Dr. Sunil Sharma discusses the medication and its uses for treating this cancer.